

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

KERYX BIOPHARMACEUTICALS INC

Form 8-K

July 14, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): JULY 11, 2005

KERYX BIOPHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

DELAWARE	000-30929	13-4087132
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

750 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

ITEM 8.01. OTHER EVENTS.

On July 11, 2005, Keryx Biopharmaceuticals, Inc. ("Keryx") filed a registration statement on Form S-3 pursuant to Rule 462(b) of the Securities Act

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

of 1933, as amended, and General Instruction IV of Form S-3 (Registration No. 333-126494) (the "Rule 462 Registration Statement") registering an additional 780,000 shares of Keryx common stock. The Rule 462 Registration Statement related to the registration statement covering 5,000,000 shares of Keryx common stock on Form S-3 (Registration No. 333-119376) (the "Registration Statement") filed with the Securities and Exchange Commission (the "Commission") on September 29, 2004 and declared effective by the Commission on October 13, 2004. Each of the exhibits attached hereto are incorporated herein by reference and are thereby specifically incorporated by reference into the Rule 462 Registration Statement.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

The following exhibits are filed as a part of this report:

EXHIBIT NUMBER -----	DESCRIPTION -----
23.1	Consent of KPMG LLP
23.2	Consent of Deloitte & Touche LLP

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KERYX BIOPHARMACEUTICALS, INC.
(Registrant)

Date: July 14, 2005

By: /s/ Ron Bentsur

Ron Bentsur
Vice President, Finance and
Investor Relations

INDEX TO EXHIBITS

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

EXHIBIT NUMBER -----	DESCRIPTION -----
23.1	Consent of KPMG LLP
23.2	Consent of Deloitte & Touche LLP